

|   |            |
|---|------------|
| INTRODUCTION .....  | XIII       |
| STUDY GOALS AND OBJECTIVES .....                                    | XIII       |
| SCOPE OF STUDY .....  | XIII       |
| METHODOLOGY AND INFORMATION SOURCES.....                            | XIV        |
| ANALYST CREDENTIALS.....  | XIV        |
| RELATED BCC REPORTS .....   | XV         |
| BCC ONLINE SERVICES.....  | XVII       |
| DISCLAIMER .....  | XVII       |
| <br>  |            |
| EXECUTIVE SUMMARY .....   | XVIII      |
| <i>SUMMARY TABLE WORLDWIDE MARKET SIZE OF BLOOD DISORDER</i>        |            |
| <i>TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS,</i>       |            |
| <i>THROUGH 2008 (\$ MILLIONS).....</i>                              | <i>XIX</i> |
| <i>SUMMARY FIGURE WORLDWIDE MARKET SIZE OF BLOOD DISORDER</i>       |            |
| <i>TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-</i> |            |
| <i>2008 (\$ MILLIONS) .....</i>                                     | <i>XX</i>  |
| <br>  |            |
| INDUSTRY OVERVIEW.....  | 1          |
| STRUCTURE AND FUNCTION OF THE HEMATOLOGICAL                         |            |
| SYSTEM.....   | 1          |
| BONE MARROW .....   | 1          |
| BLOOD CELLS .....   | 1          |
| Red Blood Cells .....   | 1          |
| White Blood Cells .....   | 2          |
| Platelets .....   | 3          |
| SPLEEN.....   | 3          |
| LYMPH SYSTEM.....   | 4          |
| LIVER .....   | 5          |
| NORMAL CLOTTING MECHANISMS .....                                    | 5          |
| EFFECTS OF AGING ON THE HEMATOLOGIC SYSTEM .....                    | 6          |
| BLOOD-RELATED MEDICAL CONDITIONS .....                              | 7          |
| ANEMIA .....  | 7          |
| <i>TABLE 1 COMMON CAUSES OF ANEMIA .....</i>                        | <i>7</i>   |
| Anemia (Continued) .....  | 8          |
| Anemia (Continued) .....  | 9          |
| Anemia Caused by Decreased Erythrocyte Production .....             | 10         |
| Iron Deficiency Anemia .....  | 10         |
| Thalassemia .....   | 11         |
| Megaloblastic Anemia .....  | 12         |
| Vitamin B12 Deficiency.....   | 12         |
| Anemia of Chronic Disease .....                                     | 12         |
| Aplastic Anemia.....  | 13         |

|  |    |
|--|----|
| Anemia Caused by Blood Loss .....  | 13 |
| Anemia Caused by Increased Erythrocyte Destruction.....                    | 13 |
| Sickle Cell Disease.....   | 14 |
| Glucose-6-Phosphate Dehydrogenase Deficiency.....                          | 14 |
| Acquired Hemolytic Anemia .....  | 14 |
| Polycythemia.....  | 15 |
| TABLE 2 TYPES OF ANEMIA .....  | 16 |
| TABLE 2 (CONTINUED) .....  | 17 |
| TABLE 2 (CONTINUED) .....  | 18 |
| HEMOPHILIA.....  | 18 |
| TABLE 3 COMMON CAUSES OF HEMOPHILIA .....                                  | 19 |
| NEUTROPENIA.....   | 19 |
| TABLE 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA.....                       | 20 |
| TABLE 5 COMMON MEDICATION CAUSES OF ANEMIA.....                            | 20 |
| THROMBOCYTOPENIA .....   | 20 |
| TABLE 6 COMMON CAUSES OF THROMBOCYTOPENIA .....                            | 21 |
| THROMBOSIS .....   | 21 |
| Thromboembolus .....   | 22 |
| Deep Vein Thrombosis.....  | 22 |
| TABLE 7 COMMON CAUSES OF THROMBOSIS .....                                  | 23 |
| DEMOGRAPHICS .....   | 23 |
| TABLE 8 ESTIMATED U.S. CASES OF SELECTED CHRONIC                           |    |
| CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, 2003 .....              | 24 |
| FIGURE 1 ESTIMATED U.S. CASES OF SELECTED LEADING CHRONIC                  |    |
| CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, 2003 .....              | 25 |
| TABLE 9 ESTIMATED WORLDWIDE CASES OF SELECTED CHRONIC                      |    |
| CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, 2003 .....              | 25 |
| TABLE 9 (CONTINUED) .....  | 26 |
| FIGURE 2 ESTIMATED WORLDWIDE CASES OF SELECTED LEADING CHRONIC             |    |
| CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, 2003 .....              | 27 |
| TABLE 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF          |    |
| TOTAL POPULATION, THROUGH 2008 (MILLIONS) .....                            | 28 |
| FIGURE 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2002-2008 (MILLIONS)..... | 28 |
| TABLE 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY                |    |
| PERCENT OF TOTAL POPULATION, THROUGH 2008 (MILLIONS).....                  | 29 |
| FIGURE 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2002, 2003           |    |
| AND 2008 (MILLIONS).....   | 29 |
| LICENSING DISPUTES .....   | 30 |
| AMGEN AND ORTHO BIOTECH .....  | 30 |
| EPOGEN.....  | 30 |
| PROCRIT .....  | 30 |
| AMGEN AND TRANSKARYOTIC TECHNOLOGIES .....                                 | 31 |
| EDUCATION/RESOURCES .....  | 32 |
| TELEMEDICINE FOR HEMOPHILIA .....  | 32 |
| EDUCATION.....   | 33 |

|   |           |
|---|-----------|
| REIMBURSEMENT ISSUES.....                                     | 33        |
| COST .....  | 34        |
| PHARMACEUTICAL LANDSCAPE CHANGES .....                        | 35        |
| IMPACT OF BIOTECHNOLOGY .....                                 | 36        |
| <i>TABLE 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS .....</i> | <i>37</i> |
| <i>TABLE 12 (CONTINUED) .....</i>                             | <i>38</i> |
| <i>TABLE 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT.....</i>    | <i>38</i> |
| <i>TABLE 13 (CONTINUED) .....</i>                             | <i>39</i> |
| Biotechnology Products on the Market for Blood Disorders..... | 39        |
| Recombinant Human Erythropoietin.....                         | 39        |
| Leukine.....  | 40        |
| Neupogen.....   | 40        |
| ReoPro .....  | 41        |
| Retavase .....  | 42        |
| Activase .....  | 42        |
| Integrilin .....  | 42        |
| Angiomax.....   | 42        |
| TNKase.....   | 43        |
| COMPUTERS, LIFESTYLE, AND DVT.....                            | 43        |
| MEDICARE AND THE ELDERLY .....                                | 43        |
| Medicare and the Elderly (Continued) .....                    | 44        |
| Medicare and the Elderly (Continued) .....                    | 45        |
| AIRLINE TRAVEL ISSUES .....                                   | 46        |
| Solutions to Airline-Caused DVT.....                          | 47        |
| PHARMACEUTICAL REBATE ISSUES.....                             | 48        |
| Rebate System Complexity .....                                | 49        |
| PRODUCT SEGMENTS BY TYPE.....                                 | 50        |
| ANEMIA TREATMENTS .....                                       | 50        |
| Anabolic Steroids .....                                       | 50        |
| Cyanocobalamin and Combinations .....                         | 50        |
| Erythropoiesis Stimulants .....                               | 51        |
| Folic Acid and Derivatives .....                              | 52        |
| Iron and Derivatives.....                                     | 53        |
| HEMOPHILIA TREATMENTS.....                                    | 53        |
| Antihemophilic Factor.....                                    | 53        |
| Anti-Inhibitor Coagulant Complex .....                        | 54        |
| Factor IX Complex.....  | 55        |
| NEUTROPENIA TREATMENTS.....                                   | 55        |
| Granulocyte Colony Stimulating Factor.....                    | 55        |
| Granulocyte Macrophage Colony Stimulating Factor .....        | 56        |
| THROMBOSIS TREATMENTS .....                                   | 56        |
| Anticoagulants.....   | 56        |

|  |           |
|--|-----------|
| Antiplatelet Agents.....   | 57        |
| Antithrombin III Agents .....  | 58        |
| Thrombin Inhibitors .....  | 59        |
| Thrombolytic Agents .....  | 60        |
| <b>MARKET SIZE AND GROWTH .....</b>  | <b>61</b> |
| <i>TABLE 14 WORLDWIDE MARKET SIZE OF BLOOD DISORDER TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....                          | 61        |
| <i>FIGURE 5 WORLDWIDE MARKET SIZE OF BLOOD DISORDER TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....                             | 62        |
| <b>BLOOD DISORDER TREATMENT MARKET BY GEOGRAPHY .....</b>  | <b>62</b> |
| <i>TABLE 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> ..... | 63        |
| <i>FIGURE 6 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....    | 63        |
| <b>BLOOD DISORDER TREATMENT MARKETS BY SEGMENT .....</b>   | <b>63</b> |
| <b>ANEMIA TREATMENTS MARKET .....</b>  | <b>63</b> |
| <i>TABLE 16 WORLDWIDE MARKET SIZE OF ANEMIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....                                  | 64        |
| <i>FIGURE 7 WORLDWIDE MARKET SIZE OF ANEMIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....                                     | 64        |
| <i>TABLE 17 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....         | 65        |
| <i>FIGURE 8 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....            | 65        |
| <b>HEMOPHILIA TREATMENTS MARKET .....</b>  | <b>66</b> |
| <i>TABLE 18 WORLDWIDE MARKET SIZE OF HEMOPHILIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....                              | 66        |
| <i>FIGURE 9 WORLDWIDE MARKET SIZE OF HEMOPHILIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....                                 | 66        |
| <i>TABLE 19 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....     | 67        |
| <i>FIGURE 10 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS)</i> .....       | 67        |
| <b>NEUTROPENIA TREATMENTS MARKET .....</b>   | <b>68</b> |
| <i>TABLE 20 WORLDWIDE MARKET SIZE OF NEUTROPENIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS)</i> .....                             | 68        |

|   |    |
|---|----|
| FIGURE 11 WORLDWIDE MARKET SIZE OF NEUTROPENIA TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS) .....                                 | 69 |
| TABLE 21 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS).....       | 69 |
| FIGURE 12 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS).....         | 70 |
| THROMBOSIS TREATMENTS .....   | 70 |
| TABLE 22 WORLDWIDE MARKET SIZE OF THROMBOSIS TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS).....                                 | 71 |
| FIGURE 13 WORLDWIDE MARKET SIZE OF THROMBOSIS TREATMENTS BY REVENUES AT MANUFACTURERS' SALES LEVELS, 2001-2008 (\$ MILLIONS).....                                   | 71 |
| TABLE 23 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2008 (\$ MILLIONS).....        | 72 |
| FIGURE 14 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET AT MANUFACTURERS' SALES LEVELS, 2001-2003 AND 2008 (\$ MILLIONS)..... | 72 |
| RESEARCH AND DEVELOPMENT.....   | 73 |
| TABLE 24 SELECTED BLOOD DISORDER TREATMENTS IN DEVELOPMENT.....   | 73 |
| TABLE 24 (CONTINUED) .....  | 74 |
| TREATMENTS AWAITING APPROVAL/PHASE TRIALS .....   | 75 |
| AWAITING APPROVAL.....  | 75 |
| Advate .....  | 75 |
| Angiomax .....  | 75 |
| Hemopure.....   | 76 |
| PHASE III CLINICAL TRIALS.....  | 76 |
| Dynepo .....  | 76 |
| Flocor.....   | 77 |
| Eculizumab .....  | 77 |
| Exanta .....  | 77 |
| Idraparinux.....  | 78 |
| PolyHeme .....  | 78 |
| Procrit .....   | 78 |
| Refacto AF.....   | 78 |
| Rituxan.....  | 79 |
| PHASE II CLINICAL TRIALS .....  | 79 |
| 424323 .....  | 79 |
| AMD3100 .....   | 79 |
| AZD6140 .....   | 80 |
| CERA.....   | 80 |
| Decitabine .....  | 80 |

|   |    |
|---|----|
| Hemolink.....   | 80 |
| Hemoxin.....  | 81 |
| ICA-17043.....  | 81 |
| MARstem.....  | 81 |
| R744.....   | 82 |
| Razaxaban.....  | 82 |
| rNAPc2.....   | 82 |
| PHASE I CLINICAL TRIALS.....  | 83 |
| 251353.....   | 83 |
| 40SD02.....   | 83 |
| AZD9684.....  | 83 |
| BAY 59-7939.....  | 84 |
| Coagulin-B.....   | 84 |
| DX-88.....  | 84 |
| Factor VIII Gene Therapy.....   | 84 |
| GH9001.....   | 85 |
| Iron Chelator.....  | 85 |
| Toleragen.....  | 85 |
| PLD-117.....  | 85 |
| PT-100.....   | 85 |
| R1516.....  | 85 |
| SR 123781.....  | 86 |
| ATryn.....  | 86 |
| INDUSTRY STRUCTURE.....   | 87 |
| COMPETITIVE ANALYSIS.....   | 87 |
| TABLE 25 TOTAL WORLDWIDE MANUFACTURERS' MARKET SHARES OF BLOOD<br>DISORDER TREATMENTS BY REVENUES AT MANUFACTURERS' SALES<br>LEVELS, 2003.....    | 87 |
| FIGURE 15 TOTAL WORLDWIDE MANUFACTURERS' MARKET SHARES OF<br>BLOOD DISORDER TREATMENTS, BY REVENUES, AT MANUFACTURERS'<br>SALES LEVELS, 2003..... | 88 |
| INDUSTRY PARTICIPANTS BY PRODUCT TYPE.....  | 89 |
| TABLE 26 BLOOD DISORDER TREATMENT MANUFACTURERS BY PRODUCT<br>TYPE, 2003.....   | 90 |
| TABLE 26 (CONTINUED).....   | 91 |
| PATENTS.....  | 92 |
| PATENT ANALYSIS BY MANUFACTURER.....  | 92 |
| TABLE 27 SELECTED MANUFACTURER PATENTS FOR BLOOD DISORDER AND<br>RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT.....                             | 92 |
| PATENTS BY APPLICATION.....   | 92 |
| Anemia Applications.....  | 92 |

|  |           |
|--|-----------|
| Hemophilia.....  | 93        |
| Neutropenia .....  | 93        |
| Thrombosis.....  | 93        |
| LEADING MARKET MANUFACTURERS .....                                 | 93        |
| <i>TABLE 28 PATENT ANALYSIS BY SELECTED LEADING BLOOD DISORDER</i> |           |
| <i>TREATMENT MANUFACTURERS, 1976–PRESENT .....</i>                 | <i>94</i> |
| COMPANY PROFILES .....   | 95        |
| ABBOTT LABORATORIES.....   | 95        |
| HISTORY.....   | 95        |
| AMGEN, INC. ....   | 95        |
| HISTORY.....   | 96        |
| ASTRAZENECA, PLC .....   | 96        |
| HISTORY.....   | 96        |
| AVENTIS BEHRING.....   | 97        |
| HISTORY.....   | 97        |
| BAXTER INTL., INC. ....  | 97        |
| HISTORY.....   | 98        |
| BAYER AG .....   | 98        |
| HISTORY.....   | 98        |
| BIOPURE CORP.....  | 98        |
| HISTORY.....   | 99        |
| BRISTOL-MYERS SQUIBB CO.....                                       | 99        |
| HISTORY.....   | 99        |
| BOEHRINGER INGELHEIM, GMBH .....                                   | 100       |
| HISTORY.....   | 100       |
| CHUGAI PHARMACEUTICAL CO., LTD. ....                               | 100       |
| HISTORY.....   | 101       |
| ELI LILLY & COMPANY.....   | 101       |
| HISTORY.....   | 101       |
| GENENTECH, INC. ....   | 101       |
| HISTORY.....   | 102       |
| GLAXOSMITHKLINE, PLC .....   | 102       |
| HISTORY.....   | 103       |
| MILLENNIUM PHARMACEUTICALS, INC.....                               | 103       |
| HISTORY.....   | 103       |
| NOVO NORDISK A/S.....  | 103       |
| HISTORY.....   | 104       |
| ORTHO BIOTECH PRODUCTS, LP .....                                   | 104       |
| HISTORY.....   | 104       |
| OTSUKA AMERICA, INC. ....  | 105       |
| HISTORY.....   | 105       |

|   |     |
|---|-----|
| PFIZER, INC.....  | 105 |
| HISTORY.....  | 105 |
| ROCHE.....  | 106 |
| HISTORY.....  | 106 |
| SANKYO CO., LTD.....  | 106 |
| HISTORY.....  | 107 |
| SANOFI-SYNTHELABO.....  | 107 |
| HISTORY.....  | 107 |
| SCHERING-PLOUGH CORP.....   | 108 |
| HISTORY.....  | 108 |
| SHIRE PHARMACEUTICALS GROUP, PLC.....                                 | 108 |
| HISTORY.....  | 109 |
| WYETH.....  | 109 |
| HISTORY.....  | 109 |
| APPENDICES.....   | 110 |
| COMPANY CONTACT INFORMATION.....                                      | 110 |
| TABLE 29 EXTENDED COMPANY LIST.....                                   | 110 |
| TABLE 29 (CONTINUED).....   | 111 |
| TABLE 29 (CONTINUED).....   | 112 |
| TABLE 29 (CONTINUED).....   | 113 |
| TABLE 29 (CONTINUED).....   | 114 |
| TABLE 29 (CONTINUED).....   | 115 |
| TABLE 29 (CONTINUED).....   | 116 |
| TABLE 29 (CONTINUED).....   | 117 |
| TABLE 29 (CONTINUED).....   | 118 |
| BLOOD DISORDER ASSOCIATIONS AND RESOURCES CONTACT<br>INFORMATION..... | 118 |
| BLOOD DISORDER ASSOCIATIONS AND RESOURCES<br>(CONTINUED).....         | 119 |
| BLOOD DISORDER ASSOCIATIONS AND RESOURCES<br>(CONTINUED).....         | 120 |